The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Social Media: Risks and Benefits
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use.
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer
May 10th 2024Patients with high-risk prostate cancer treated with apalutamide with androgen deprivation therapy following radical prostatectomy had a recurrence-free survival rate of 100% after 2 years.
What New Cancer Drugs Were Approved in 2023?
January 1st 2024In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
May 9th 2024Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
December 14th 2023Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention
May 8th 2024A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.
Noninvasive Stool RNA Screening Test for CRC Receives FDA Approval
May 7th 2024A screening test has been approved by the FDA for adults 45 years of age or older with an average risk for developing colorectal cancer.
Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer
May 10th 2024Patients with high-risk prostate cancer treated with apalutamide with androgen deprivation therapy following radical prostatectomy had a recurrence-free survival rate of 100% after 2 years.
What New Cancer Drugs Were Approved in 2023?
January 1st 2024In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
May 9th 2024Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
December 14th 2023Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention
May 8th 2024A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.
Noninvasive Stool RNA Screening Test for CRC Receives FDA Approval
May 7th 2024A screening test has been approved by the FDA for adults 45 years of age or older with an average risk for developing colorectal cancer.
Latest Conference Coverage
Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention